Calreticulin Is a Negative Regulator of Bronchial Smooth Muscle Cell Proliferation. (21st February 2012)

• Record Type: Journal Article
• Authors: Miglino, Nicola; Roth, Michael; Lardinois, Didier; Tamm, Michael; Borger, Peter
• Other Names: Heijink Irene Academic Editor.
• Is Part Of: Journal of allergy. Volume 2012(2012)
• Publication Date: 2012-02-21
• Subjects: Allergy -- Periodicals; Immunologic diseases -- Periodicals; Allergy and Immunology; Hypersensitivity; Immune System Diseases; Allergy; Immunologic diseases; Electronic journals; Periodical; Periodicals; 616.97
• DOI: 10.1155/2012/783290
• Languages: English
• ISSNs: 1687-9783

Abstract

Abstract : Background . Calreticulin controls the C/EBP α p42/p30 at the translational level trough a cis-regulatory CNG rich loop in the CEBPA mRNA. We determined the effects of steroids and long-acting beta-agonists on the p42/p30 ratio and on calreticulin expression in primary human bronchial smooth muscle (BSM) cells. Methods . The effects of budesonide (10 −8 M) and formoterol (10 −8 M) were studied in BSM cells pre-treated with siRNA targeting calreticulin. The expression of C/EBP α and calreticulin was determined by immuno-blotting. Automated cell counts were performed to measure proliferation. Results . All tested BSM cell lines (n = 5 ) expressed C/EBP α and calreticulin. In the presence of 5% FBS, the p42/p30 ratio significantly decreased (n = 3, P < 0.05 ) and coincided with BSM cell proliferation. High levels of calreticulin were associated with a decreased p42/p30 isoform ratio. FBS induced the expression of calreticulin (n = 3, P < 0.05 ), which was further increased by formoterol. siRNA targeting calreticulin increased the p42/p30 ratio in non-stimulated BSM cells and significantly inhibited the proliferation of PDGF-BB-stimulated BSM cells (n = 5, P < 0.05 ). Neither budesonide nor formoterol restored the p42 isoform expression. Conclusions . Our data show calreticulin is a negative regulator of C/EBP α protein expression in BSM cells. Modulation of calreticulin levels may provide a novel target to reduce BSM remodeling.